GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aelis Farma SA (XPAR:AELIS) » Definitions » EBIT

Aelis Farma (XPAR:AELIS) EBIT : €-4.92 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Aelis Farma EBIT?

Aelis Farma's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was €-3.36 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was €-4.92 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Aelis Farma's annualized ROC % for the quarter that ended in Dec. 2023 was -90.91%. Aelis Farma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -554.46%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Aelis Farma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3.14%.


Aelis Farma EBIT Historical Data

The historical data trend for Aelis Farma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aelis Farma EBIT Chart

Aelis Farma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial -3.07 -2.90 1.90 -14.18 -4.92

Aelis Farma Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.32 -10.31 -3.86 -1.56 -3.36

Competitive Comparison of Aelis Farma's EBIT

For the Biotechnology subindustry, Aelis Farma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aelis Farma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aelis Farma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Aelis Farma's EV-to-EBIT falls into.



Aelis Farma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-4.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aelis Farma  (XPAR:AELIS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Aelis Farma's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-8.038 * ( 1 - 0.03% )/( (11.506 + 6.172)/ 2 )
=-8.0355886/8.839
=-90.91 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Aelis Farma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-6.72/( ( (1.24 + max(-7.308, 0)) + (1.184 + max(-4.442, 0)) )/ 2 )
=-6.72/( ( 1.24 + 1.184 )/ 2 )
=-6.72/1.212
=-554.46 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.095 + 5.011) - (3.45 + 0 + 8.964)
=-7.308

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.759 + 0.053 + 2.684) - (5.271 + 0 + 3.667)
=-4.442

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Aelis Farma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-4.916/156.803
=-3.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aelis Farma EBIT Related Terms

Thank you for viewing the detailed overview of Aelis Farma's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Aelis Farma (XPAR:AELIS) Business Description

Traded in Other Exchanges
Address
146, rue Leo Saignat, Bordeaux, FRA, 33077
Aelis Farma SA is a biotechnology Company specializing in the research and development of treatment's related to brain diseases.

Aelis Farma (XPAR:AELIS) Headlines

No Headlines